drugset
drugset / Trial / NCT01155258

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT01155258 ↗

Phase 1 Completed 19 enrolled University of Southern California Wyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.

Timeline

Start
2010-06
Primary completion
2013-01
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule — Intravenous
Subject Vinorelbine Small molecule — Intravenous

Indications

PPoma carcinoid tumor cervical carcinoma cutaneous neuroendocrine carcinoma endometrial carcinoma hereditary pheochromocytoma-paraganglioma male breast carcinoma medullary thyroid gland carcinoma non-small cell lung carcinoma ovarian carcinoma ovarian germ cell tumor pancreatic endocrine carcinoma paraganglioma pheochromocytoma prostate carcinoma renal cell carcinoma small cell lung carcinoma uterine corpus sarcoma